Psyence Biomedical (Psyence Biomedical) EPS (Basic) : $ (TTM As of Mar. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical EPS (Basic)?

Psyence Biomedical's basic earnings per share (Basic EPS) for the six months ended in Mar. 2023 was $-0.24. Psyence Biomedical does not have enough years/quarters to calculate its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2023.

Psyence Biomedical's EPS (Diluted) for the six months ended in Mar. 2023 was $-0.24. Psyence Biomedical does not have enough years/quarters to calculate its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023.

Psyence Biomedical's EPS without NRI for the six months ended in Mar. 2023 was $-0.25. Psyence Biomedical does not have enough years/quarters to calculate its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Psyence Biomedical EPS (Basic) Historical Data

The historical data trend for Psyence Biomedical's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical EPS (Basic) Chart

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

EPS (Basic)

-0.14

-0.24

Psyence Biomedical Semi-Annual Data
	Mar21	Mar22	Mar23
EPS (Basic)	-	-0.14	-0.24

Psyence Biomedical EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Psyence Biomedical's Basic EPS for the fiscal year that ended in Mar. 2023 is calculated as

Basic EPS (A: Mar. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.097	-	0)	/	12.745
	=	-0.24

Psyence Biomedical's Basic EPS for the quarter that ended in Mar. 2023 is calculated as

Basic EPS (Q: Mar. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.097	-	0)	/	12.745
	=	-0.24

Psyence Biomedical (NAS:PBM) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Psyence Biomedical EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical (Psyence Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines

From GuruFocus

Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus?

By PRNewswire • 02-12-2024